At GlaxoSmithKline (GSK) high ethical standards in R&D are key to protecting participants in our clinical research, ensuring the quality of our research, and maximising the benefits and minimising the risks of our medicines and vaccines. High ethical standards are also essential for us to obtain regulatory approval for new medicines, and for patients and doctors to put their trust in our research programmes and products. Our R&D policies are global and we apply the same high research standards wherever we operate, including for research conducted by contract organisations on our behalf. We have rigorous procedures and assurance processes to ensure clinical trials of our medicines are conducted according to the Good Clinical Practice (GCP) guidelines .
GSK is committed to focusing on the patient in everything that we do and our R&D pipeline is central to our ability to meet patients' needs. We are committed to being open about the results of our clinical research and use a number of reporting channels so that those who evaluate the efficacy and safety of our medicines or use our medicines can make informed decisions on their use. As part of our commitment to understand patient needs, and to develop better medicines, we have a programme of activities where we invite patients to discuss their conditions with our research teams.
We recognise that biomedical research can raise ethical concerns and refer to guidance from national and international groups to inform our research activities. GSK is pleased therefore to support EFGCP in its purpose to promote good clinical practice and encourage the practice of common, high-quality standards in all stages of biomedical research.